• 1
    Pansuriya TC, Kroon HM, Bovee JVMG. Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol 2010; 3: 55769.
  • 2
    Verdegaal SHM, Bovee JVMG, Pansuriya TC et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist 2011; 16: 17719.
  • 3
    Schwarz HS, Zimmerman NB, Simon MA et al. The malignant potential of enchondromatosis. J Bone Joint Surg Am 1987; 69: 26974.
  • 4
    Patrick SW, Jay P, David RW et al. The common feature of leukemia associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-Hydroxyglutarate. Cancer Cell 2010; 17: 22534.
  • 5
    Gupta R, Webb-Myers R, Flanagan S et al. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 2011; 64: 83544.
  • 6
    Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 76573.
  • 7
    Pansuriya TC, Eijk RV, d`Adamo P et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43: 125661.
  • 8
    Amary MF, Damato S, halai D et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011; 43: 12627.
  • 9
    Bathla G, Gupta S, Ong CK. Multifocal intracranial astrocytoma in a pediatric patient with Ollier disease. Indian J Radiol Imaging 2012; 22: 5862.
  • 10
    Walid MS, Troup EC. Cerebellar anaplastic astrocytoma in a teenager with Ollier Disease. J Neurooncol 2008; 89: 5962.
  • 11
    Pearce P, Robertson T, Ortiz-Gomez JD et al. Multifocal supratentorial diffuse glioma in a young patient with Ollier disease. J Clin Neurosci 2012; 19: 4778.
  • 12
    Liu X, Kato Y, Kaneko MK et al. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med 2013; 2: 80314.
  • 13
    Kaneko MK, Ogasawara S, Kato Y. Establishment of a novel multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations. Tohoku J Exp Med 2013; 230: 1039.
  • 14
    Ogasawara S, Kaneko MK, Tsujimoto Y, Liu X, Kato Y. Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations. Monoclon Antib Immunodiagn Immunother 2013; 32: 37781.